Literature DB >> 17438054

Isoniazid induces its own resistance in nonreplicating Mycobacterium tuberculosis.

Salman Siddiqi1, Param Takhar, Christian Baldeviano, William Glover, Ying Zhang.   

Abstract

Isoniazid (INH) resistance is most frequent among drug-resistant Mycobacterium tuberculosis clinical isolates. This study was conducted to investigate whether INH could induce its own resistance. During INH susceptibility testing in BACTEC 12B and MGIT 960 media, weekly subcultures were made from the drug-containing media into fresh medium without drug and susceptibility testing was performed. Rifampin (RIF) was used as a control drug. M. tuberculosis H37Rv and three clinical isolates were tested in this study. INH-resistant subcultures were analyzed for catalase activity, INH susceptibility, and mutations associated with INH resistance. With inoculum size (10(4) bacilli) smaller than a size that contains spontaneously INH-resistant mutants, INH was found to induce resistance to itself in INH-tolerant persisters but not to other drugs. The minimum time required for induction of INH resistance was 5 to 6 days. In contrast, RIF did not induce RIF resistance. Eight subcultures with INH-induced resistance were analyzed, and two had a MIC of 0.4 microg/ml INH and six had MICs of over 2 microg/ml INH. Four of the eight subcultures with INH-induced resistance had lost catalase activity, with three having katG mutations. Despite being a powerful frontline tuberculosis drug, INH has the potential drawback of inducing its own stable genetic resistance in INH-tolerant persisters. This finding helps to explain the higher frequency and prevalence of INH-resistant isolates than isolates with resistance to other drugs in patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17438054      PMCID: PMC1891357          DOI: 10.1128/AAC.00086-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Isoniazid-resistant strains of tubercle bacili; their development and stability.

Authors:  M BARNETT; S R M BUSHBY; D A MITCHISON
Journal:  Lancet       Date:  1953-02-14       Impact factor: 79.321

2.  Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates.

Authors:  A S Lee; A S Teo; S Y Wong
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

3.  Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes.

Authors:  G Canetti; W Fox; A Khomenko; H T Mahler; N K Menon; D A Mitchison; N Rist; N A Smelev
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

4.  Evidence for the generation of active oxygen by isoniazid treatment of extracts of Mycobacterium tuberculosis H37Ra.

Authors:  H A Shoeb; B U Bowman; A C Ottolenghi; A J Merola
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

5.  Altered NADH/NAD+ ratio mediates coresistance to isoniazid and ethionamide in mycobacteria.

Authors:  Catherine Vilchèze; Torin R Weisbrod; Bing Chen; Laurent Kremer; Manzour H Hazbón; Feng Wang; David Alland; James C Sacchettini; William R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

Review 6.  Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease.

Authors:  D L Cohn; F Bustreo; M C Raviglione
Journal:  Clin Infect Dis       Date:  1997-01       Impact factor: 9.079

7.  Transformation with katG restores isoniazid-sensitivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentrations.

Authors:  Y Zhang; T Garbe; D Young
Journal:  Mol Microbiol       Date:  1993-05       Impact factor: 3.501

8.  inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis.

Authors:  A Banerjee; E Dubnau; A Quemard; V Balasubramanian; K S Um; T Wilson; D Collins; G de Lisle; W R Jacobs
Journal:  Science       Date:  1994-01-14       Impact factor: 47.728

9.  The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis.

Authors:  Y Zhang; B Heym; B Allen; D Young; S Cole
Journal:  Nature       Date:  1992-08-13       Impact factor: 49.962

10.  Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis.

Authors:  Miguel Viveiros; Isabel Portugal; Rosário Bettencourt; Thomas C Victor; Annemarie M Jordaan; Clara Leandro; Diane Ordway; Leonard Amaral
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

View more
  6 in total

Review 1.  Reporter phage and breath tests: emerging phenotypic assays for diagnosing active tuberculosis, antibiotic resistance, and treatment efficacy.

Authors:  Paras Jain; David S Thaler; Mamoudou Maiga; Graham S Timmins; William R Bishai; Graham F Hatfull; Michelle H Larsen; William R Jacobs
Journal:  J Infect Dis       Date:  2011-11-15       Impact factor: 5.226

2.  In Vitro and In Vivo Activity of Oxazolidinone Candidate OTB-658 against Mycobacterium tuberculosis.

Authors:  Shaochen Guo; Bin Wang; Lei Fu; Xi Chen; Weiyan Zhang; Haihong Huang; Yu Lu
Journal:  Antimicrob Agents Chemother       Date:  2021-08-16       Impact factor: 5.191

3.  New approach for drug susceptibility testing: monitoring the stress response of mycobacteria.

Authors:  Ronald J Rieder; Zhihui Zhao; Boris Zavizion
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

Review 4.  Addressing Latent Tuberculosis: New Advances in Mimicking the Disease, Discovering Key Targets, and Designing Hit Compounds.

Authors:  André Campaniço; Shrika G Harjivan; Digby F Warner; Rui Moreira; Francisca Lopes
Journal:  Int J Mol Sci       Date:  2020-11-23       Impact factor: 5.923

5.  Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis.

Authors:  Regina Wilson; Pradeep Kumar; Vijay Parashar; Catherine Vilchèze; Romain Veyron-Churlet; Joel S Freundlich; S Whitney Barnes; John R Walker; Michael J Szymonifka; Emily Marchiano; Shubhada Shenai; Roberto Colangeli; William R Jacobs; Matthew B Neiditch; Laurent Kremer; David Alland
Journal:  Nat Chem Biol       Date:  2013-06-16       Impact factor: 15.040

6.  A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles.

Authors:  Basem Battah; Giulia Chemi; Stefania Butini; Giuseppe Campiani; Simone Brogi; Giovanni Delogu; Sandra Gemma
Journal:  Molecules       Date:  2019-11-29       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.